Cyclopentane STING Modulators Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective STING activators to modulate the innate immune response, which is crucial for treating various diseases including cancer and viral infections, as existing modulators are limited in clinical application.
Innovation Solution
Development of cyclopentane-based compounds that bind to STING, inducing type 1 interferons and cytokines, offering potential as both activators and antagonists for treating inflammatory, autoimmune, and cancerous conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclopentane-based compounds are developed as STING modulators, then the ability to stimulate innate immune response and induce type 1 interferons is improved, but the lack of effective STING activators in current therapies is addressed
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical structures of cyclopentane-based compounds (modifying R1, R2, and W substituents) to optimize STING binding affinity and biological activity. This approach transforms the molecular parameters of the compounds to achieve reliable STING activation while exploring different therapeutic applications
Solution Approach 2:
The invention achieves versatility by designing compounds that can function as both STING activators and antagonists depending on their specific chemical structure. This multi-functionality allows the same class of compounds to be applied across diverse clinical indications including cancer, viral infections, and inflammatory diseases
2Productivity
If small molecule compounds are designed to bind STING, then the induction of type 1 INF and cytokines is enhanced, but the limitation of few effective STING activators is overcome
Solution Approach 1:
The patent systematically modifies chemical parameters of cyclopentane-based compounds including substituent types (R1, R2 groups), phosphate ester configurations, and stereochemistry to enhance immunomodulatory activity. These parameter optimizations produce compounds with improved cytokine induction capabilities and clinical potential
3Strength
If cyclopentane-based compounds with specific substituents are synthesized, then the binding affinity to STING is improved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (hydroxyl, alkoxy, halogen substituents) at particular positions on the cyclopentane ring structure. This localized modification approach enhances STING binding affinity at specific molecular interaction sites without requiring complex changes throughout the entire molecular structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively stimulate the innate immune response, providing a promising strategy for treating cancer, viral infections, and other inflammatory conditions by upregulating STING activity and increasing interferon-beta levels.
Implementation Method 1
Certain compounds of the invention have been shown to bind to STING and to induce type 1 INF and other cytokines
Data Source
AI summary
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.